Interventional Cardiology News and Research

RSS

Cappella introduces new Sideguard stent; expands commercial operations

Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announces that an additional diameter has been added to the Sideguard® platform.

26 Oct 2009

CHMP grants positive opinion to extend the use of Angiox to patients undergoing PCI

The Medicines Company announced today that the Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion applicable to all Member States of the European Union/European Economic Area that will extend the use of Angiox (bivalirudin) to include patients with heart attacks (so-called ST segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI).

24 Oct 2009

PLC Systems' RenalGuard to be utilized in a live case transmission at the GISE 2009 conference

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that its RenalGuard System(TM) will be utilized as part of a live case transmission from the Clinica Mediterranea, Naples, Italy, to the 30th Congresso Nazionale della Societa' Italiana di Cardiologia Invasiva (GISE) during the conference.

19 Oct 2009

Medtronic commences study of the Zotarolimus-Eluting Peripheral Stent System for treating erectile dysfunction

Medtronic, Inc., announced today the initiation of a feasibility study of an interventional treatment for erectile dysfunction (ED) that uses a specially-designed drug-eluting stent system.

14 Oct 2009

Clarian Cardiovascular offers transradial cardiac catheterization

Clarian Cardiovascular has established the Midwest’s only Transradial Center of Excellence in an effort to offer patients a catheterization procedure that significantly reduces recovery time and improves patient outcomes – transradial cardiac catheterization.

9 Oct 2009

Boston Scientific, Johnson & Johnson resolve patent disputes through settlement

Boston Scientific Corporation today announced the settlement of more than a dozen lawsuits involving Johnson & Johnson, including the Palmaz-NIR suit. All the disputes involved intellectual property in the interventional cardiology arena. In connection with the settlement, Boston Scientific will make a payment of $716 million to Johnson & Johnson. The settlement payment is within Boston Scientific's existing reserve for the Palmaz-NIR suit and will be made from existing cash on hand.

1 Oct 2009

St. Jude Medical's cardiovascular healthcare portfolio to be presented at TCT meeting

St. Jude Medical, Inc. (NYSE:STJ) today announced it will display products and technologies from the company’s portfolio of solutions for cardiovascular healthcare professionals at the 21st annual Transcatheter Cardiovascular Therapeutics meeting in San Francisco. The featured products reflect the company’s continued commitment to developing comprehensive, high-performance solutions which advance the practice of interventional cardiology by improving efficiencies and giving physicians more control.

23 Sep 2009

Breakthrough in the successful treatment of AMI

Medical device pioneer Stentys announced today the results on 20 patients participating in the Company’s ‘APPOSITION I’ clinical study—the world’s first to treat patients with acute myocardial infarction (AMI) via a self-expanding stent. These data were disclosed today by the study’s principal investigator, Christian Spaulding, M.D., Ph.D., to an audience of cardiologists during a Stentys-hosted satellite meeting at the Transcatheter Cardiovascular Therapeutics (“TCT”) 2009 annual scientific meeting.

23 Sep 2009

FDA approves Cordis Corporation's 2.25 mm CYPHER Stent

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world’s most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.

22 Sep 2009

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard System(TM) at Transcatheter Cardiovascular Therapeutics (TCT) 2009, sponsored by the Cardiovascular Research Foundation, September 21 - 25, 2009, in San Francisco, California. More than 11,000 clinicians and professionals are expected to attend this event.

21 Sep 2009

Abbott introduces XIENCE PRIME Everolimus Eluting Coronary Stent System for global market

Abbott (NYSE: ABT) today announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

31 Aug 2009

Initial abstract for the clinical study of PLC's RenalGuard System published

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that the initial abstract for the investigator-sponsored clinical study of its RenalGuard System(TM) has been published, in advance of the annual meeting of the European Society of Cardiology, August 29 - September 2, 2009 in Barcelona, Spain, on the ESC website.

26 Aug 2009

First patient enrolled for IDEV Technologies' SUPERB clinical trial

IDEV(R) Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced that the first patient was enrolled in the Company's FDA-approved multi-center clinical trial of its self-expanding SUPERA(R) stent, a novel stent platform designed for the treatment of biliary and peripheral artery disease (PAD) in the superficial femoral artery (SFA).

25 Aug 2009

TCT Featured Clinical Trials to be presented on September 24 in San Francisco

A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.

21 Aug 2009

Studies indicate why females do not fare as well as men in undergoing angioplasty for heart attacks

Age, condition and treatment delay are among the reasons women who undergo angioplasty for heart attack often do not fare as well as do men, according to two studies presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual Scientific Sessions.

6 May 2009

Hybrid cardiac revascularization procedures

Patients with coronary artery disease -- blockages of the vessels that feed the heart -- can be treated in a number of ways.

6 Apr 2009

Requirement for pediatric cardiac devices highlighted by off-label procedures

Nearly two-thirds of children who undergo routine interventional cardiology procedures -- those involving a catheter to treat structural disorders of the heart -- may be receiving treatment with a device that's being used for an off-label application.

30 Mar 2009

Study offers closer look at Takotsubo cardiomyopathy

"Broken heart syndrome" is still a mystery to many in the medical community, but new data from researchers at The Miriam Hospital may shed some light on the clinical characteristics and outcomes of this relatively rare, life-threatening condition.

29 Mar 2009

Combination of very low LDL and normal systolic blood pressure attenuate coronary artery disease

New data published in the March 31, 2009, issue of the Journal of the American College of Cardiology show that patients with coronary artery disease (CAD) who achieve very low levels of low-density lipoprotein (LDL) cholesterol along with normal systolic blood pressure have the slowest progression of CAD.

23 Mar 2009

Bioabsorbable stents show promise

A study published online in The Lancet presented two year data for the bioabsorbable everolimus coronary stent.

15 Mar 2009